Publications by authors named "Isabelle Fajac"

Claim this Profile
T
The Clinical, Psychosocial and Economic Burden of Cystic Fibrosis Lung Disease in the Era of CFTR Modulator Therapy.
Isabelle Fajac, Raksha Jain, Marcus A Mall, Bruce K Rubin, Patrick A Flume

Ann Am Thorac Soc· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial.
Barry J Plant, Gisli G Einarsson, Kevin F Deasy, Darren Dahly, Pradeep K Singh, Isabelle Fajac

Eur Respir J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment.
Edith T Zemanick, Bonnie Ramsey, Dorota Sands, Edward F McKone, Isabelle Fajac

J Cyst Fibros· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of CFTR modulators in patients with interstitial lung disease caused by ABCA3 transporter deficiency.
Mathilde Le Brun, Nadia Nathan, Camille Louvrier, Marie Legendre, Severine Feuillet, Isabelle Fajac

ERJ Open Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New drugs, new challenges in cystic fibrosis care.
Isabelle Fajac, Pierre-Régis Burgel, Clémence Martin

Eur Respir Rev· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standards for the care of people with cystic fibrosis; establishing and maintaining health.
Kevin W Southern, Charlotte Addy, Scott C Bell, Amanda Bevan, Urzula Borawska, Isabelle Fajac

J Cyst Fibros· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare variants: a viewpoint.
Pierre-Régis Burgel, Isabelle Sermet-Gaudelus, Emmanuelle Girodon, Reem Kanaan, Jean Le Bihan, Isabelle Fajac

Eur Respir J· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standards for the care of people with cystic fibrosis (CF).
Kevin W Southern, Pierre-Regis Burgel, Carlo Castellani, Kris De Boeck, Jane C Davies, Isabelle Fajac

J Cyst Fibros· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy.
Katherine B Hisert, Susan E Birket, John Paul Clancy, Damian G Downey, John F Engelhardt, Isabelle Fajac

Lancet Respir Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective.
Nicole Mayer-Hamblett, John Paul Clancy, Raksha Jain, Scott H Donaldson, Isabelle Fajac

Lancet Respir Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cystic fibrosis.
Isabelle Fajac, Pierre-Régis Burgel

Presse Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AQP5, a second gene at play with CFTR in aquagenic palmoplantar keratoderma.
Brian Sperelakis-Beedham, Maureen Lopez, Emmanuelle Bourrat, Natacha Gaitch, Florence Houriez, Isabelle Fajac

J Eur Acad Dermatol Venereol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del variant.
Pierre-Régis Burgel, Isabelle Sermet-Gaudelus, Isabelle Durieu, Reem Kanaan, Julie Macey, Isabelle Fajac

Eur Respir J· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor.
Isabelle Fajac, Cori Daines, Isabelle Durieu, Jennifer L Goralski, Harry Heijerman

J Cyst Fibros· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distal Lung Inflammation Assessed by Alveolar Concentration of Nitric Oxide Is an Individualised Biomarker of Severe COVID-19 Pneumonia.
Thông Hua-Huy, Sven Günther, Christine Lorut, Marielle Subileau, Frédérique Aubourg, Isabelle Fajac

J Pers Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging medicines to improve the basic defect in cystic fibrosis.
Isabelle Fajac, Isabelle Sermet-Gaudelus

Expert Opin Emerg Drugs· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat test.
Thao Nguyen-Khoa, Aurélie Hatton, David Drummond, Laura Aoust, Joël Schlatter, Isabelle Fajac

Eur Respir J· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study.
Laurent Meijer, Geneviève Hery-Arnaud, Cyril Leven, Emmanuel Nowak, Sophie Hillion, Isabelle Fajac

J Cyst Fibros· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The journal of cystic fibrosis' 20th anniversary.
Kris De Boeck, J Stuart Elborn, Isabelle Fajac, Niels Hoiby

J Cyst Fibros· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis.
Nico Derichs, Jennifer L Taylor-Cousar, Jane C Davies, Isabelle Fajac, Elizabeth Tullis

J Cyst Fibros· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators.
Isabelle Fajac, Isabelle Sermet-Gaudelus

Curr Opin Pulm Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis.
J Stuart Elborn, Michael W Konstan, Jennifer L Taylor-Cousar, Isabelle Fajac, Alexander Horsley

J Cyst Fibros· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators.
Isabelle Fajac, Isabelle Sermet

Cells· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe.
Andreas Jung, Annalisa Orenti, Fiona Dunlevy, Elina Aleksejeva, Egil Bakkeheim, Isabelle Fajac

ERJ Open Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triple Therapy for Cystic Fibrosis -Gating and -Residual Function Genotypes.
Peter J Barry, Marcus A Mall, Antonio Álvarez, Carla Colombo, Karin M de Winter-de Groot, Isabelle Fajac

N Engl J Med· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis